Medexus Pharmaceuticals Stock
Medexus Pharmaceuticals Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- Canada
- CEO
- Kenneth d'Entremont
- Employees
- 90
- Market cap
- $154 M
- IPO
- 09/01/2014
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX…
Medexus Pharmaceuticals stock: price history
1D
+1.9%
1W
-1.0%
1M
-2.0%
6M
+23.4%
YTD
+68.4%
1Y
+76.9%
2Y
+90.7%
5Y
+39.6%
10Y
+23.4%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~36% stronger price swings than usual
Ask the agents about Medexus Pharmaceuticals
Analyst assessment of Medexus Pharmaceuticals
0
STRONG BUY
0
BUY
1
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Hold
As of: 04/01/2022
Medexus Pharmaceuticals stock metrics
P/E
-45.4
P/B
2.3
EV/EBITDA
10.26
RETURN ON EQUITY
1.1%
NET MARGIN
1.9%
DEBT/EQUITY
0.55
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
91.9%
FLOAT SHARES
28,889,742
AVG. DAILY VOLUME (30D)
35,264
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Medexus Pharmaceuticals stock
What does Medexus Pharmaceuticals do?
Medexus Pharmaceuticals Inc. is a company in the Healthcare sector, Medical - Pharmaceuticals industry, headquartered in Canada.
The CEO is Kenneth d'Entremont, the company employs around 90 people.
The IPO was on 09/01/2014; the stock trades on TSX under the ticker MDP.TO.
What do analysts say about Medexus Pharmaceuticals stock?
1 analysts rate the stock, the consensus is Hold (as of 04/01/2022).
This is an external assessment, not a statement by Market Jury.
When does Medexus Pharmaceuticals report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 36% stronger than usual.
Does Medexus Pharmaceuticals pay a dividend?
No, Medexus Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Medexus Pharmaceuticals?
Comparable stocks include Helus Pharma, Corcept Therapeutics, Liquidia, Latigo Biotherapeutics, Bausch + Lomb, AbCellera Biologics, Eli Lilly and Company and Johnson & Johnson.
How can I get Medexus Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Medexus Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.